Merck stock could take another hit Thursday after the company reported another quarter of light sales for its HPV vaccine, Gardasil.

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results beat estimates. First quarter sales were $15.5 billion, above the $15.3 ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China.

Merck & Co. Inc. managers escaped allegations that they hurt the pharmaceutical giant by misleading investors over traction ...

While HHS Secretary Kennedy frets over food dye in Froot Loops, his 2023 attack on Gardasil — a vaccine proven to prevent ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

Gardasil is a vaccine, licensed for use in June 2006, by the FDA. It targets four strains of human papillomavirus (HPV) -- HPV-6, 11, 16, and 18. HPV-16 and HPV-18 account for about 70% of all ...

The Gardasil® vaccine—called a “quadrivalent vaccine” because it protects against four HPV types (6, 11, 16, and 18)—was approved by the Food and Drug Administration in 2006 for girls and young women ...

In its rush to market its human papillomavirus vaccine, Merck forgot to make a strong and compelling case for compulsory immunization. Merck's human papillomavirus (HPV) vaccine Gardasil should ...

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...